Straits Times Index
3,084.08 -6.23 (-0.20%) S&P 500
4,564.49 -30.14 (-0.66%) Dow
36,178.08 -67.42 (-0.19%) Nasdaq
14,154.78 -150.25 (-1.05%) Bitcoin USD
41,703.88 +2,114.74 (+5.34%) CMC Crypto 200
857.70 -1.01 (-0.12%)
Takeda Pharmaceutical Company Limited (TAK)
| Previous close | 14.17 |
| Open | 14.01 |
| Bid | 14.08 x 3200 |
| Ask | 14.09 x 3000 |
| Day's range | 14.01 - 14.12 |
| 52-week range | 13.19 - 17.15 |
| Volume | |
| Avg. volume | 1,871,853 |
| Market cap | 44.178B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 34.31 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.66 (4.23%) |
| Ex-dividend date | 29 Sept 2022 |
| 1y target est | N/A |
- Business Wire
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
OSAKA, Japan & CAMBRIDGE, Mass., November 27, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that it will present 17 company-sponsored abstracts at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego. Takeda’s latest research focuses on improving treatment options for those living with hematologic diseases.
- Business Wire
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass., November 09, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein designed to address an unmet medical need in people with cTTP by replacing the defici
- Business Wire
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
OSAKA, Japan & CAMBRIDGE, Mass., November 08, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is the first and only selective
